COVID-19 and Vaccines as Risk Factors for Guillain-Barré Syndrome

Two large studies examine the risks associated with the infection and with different COVID-19 vaccine brands.

Patients with Guillain-Barré syndrome (GBS) frequently have a history of an infection or vaccination 4 to 8 weeks previously. The association of GBS with COVID-19 specifically, and with some COVID-19 vaccines, has not been conclusively shown. To draw better conclusions with respect to the risk for GBS after SARS-Cov-2 infection or exposure to COVID-19 vaccination, two new, robust studies have now been done: A population-based, nested case-control study in Israel with a cohort of 3,193,951 patients aged ≥16 years, and a French study that aimed to quantify the risk for GBS according to the brand of COVID-19 vaccine used.

Examining medical records from most of the Israeli population, Bishara and colleagues matched 76 patients diagnosed with GBS…

Reviewing Author

Jaime Toro, MD

Disclosures

Editorial BoardsMultiple Sclerosis and Related Disorders

Jaime Toro, MD

Disclosures

Editorial BoardsMultiple Sclerosis and Related Disorders

COVID-19 and Vaccines as Risk Factors for Guillain-Barré Syndrome

Topics

Reviewing Author